Monday 7 March 2016

Flu-2016

About Conference


After the success of Flu-2015OMICS International welcomes you to the 2nd International Conference on Flu to be held from October 31- November-2, 2016 in San Francisco, USA. The theme of Flu-2016 is "Scientific Milestones in Understanding and Preventing Flu" Flu- 2016 offers a unique window and opportunities to present and evidence the latest updates with a holistic approach to different areas of interest. We have done our outmost to get rid of the traditional approach in the elaboration of the programme and most importantly, during the active sessions, in order to foster innovation and scientific curiosity. Our intention is, to create platforms which will gather eminent scientists, medical professionals who will undoubtedly enrich the conference.
OMICS International organizes 1000+ Global events  every year across  the globe with support from 1200+ more scientific societies and Publishes 700 Open access journals which contains over 50000 eminent personalities, reputed scientists as editorial board members. The conference expects the  participation of experts from various cross disciplines like virologists, immunologists, microbiologists, epidemiologists, doctors, public health planners, pharmacologists, computational biologists, and those in applied fields conducting influenza related research.
The flu virus is unstable and mutates often. This virus while mostly non-lethal can easily develop the ability to kill and infect millions of people, as seen with the Spanish Flu of 1918. The scientific community must therefore work together to make sure any new influenza strain is constantly monitored and with the help of surveillance programs prevent a lethal influenza epidemic.Due to the non-stable nature of the flu virus many companies are trying to develop a universal vaccine which will work against all strains of influenza.
As the world shrinks the ease with which an infectious diseases spreads amongst the population increases exponentially. Influenza or flu as it is commonly known is one such disease. The market consists of products to prevent, treat, and diagnose influenza viruses during both seasonal and pandemic episodes. Also included in the market is the stockpiling efforts and spending on new vaccine/therapeutic contracts. The global influenza market will grow from nearly $3.8 billion in 2012 to $4 billion in 2013. Global influenza market to be worth $6.3 billion in 2014 for a compound annual growth rate (CAGR) of 2.7%.This year, the global market for products used in the fight against influenza will be worth an estimated $5.5 billion, according to a new technical market research report, the Global Influenza Market, from BCC Research. Market revenue is forecast to increase at a five-year compound annual growth rate (CAGR) of 8% from 2013 to 2018, totaling nearly $6 billion in 2018. The market is broken down into vaccines, therapeutics, and diagnostic products. The vaccines segment has the largest share of the market, worth an estimated $3.2 billion in 2009. This segment is expected to grow at a CAGR of 5.6% to reach nearly $4.2 billion in 2014. The therapeutics segment has the second-largest share of the market with $2.1 billion in 2009. But that segment is expected to decrease at a CAGR of -2.4%, falling to $1.9 billion in 2014. As many as 500,000 people die of influenza annually and with the threat of a pandemic, government agencies and disease-prevention organizations are devoted to gaining control of the situation.

Conference Highlights


  • Flu Vaccines: Current and Novel Approach
  • Pathology of Influenza Virus Infections
  • Flu Symptoms & Treatment
  • Flu Vaccine: Manufactures & Market Analysis
  • Flu Clinical Studies & Case Reports
  • Antivirals and Therapeutics
  • Flu Vaccines and Vaccination: Opportunities and Challenges for All Age Groups
  • Flu Virus -Advancements in Detection & Differentiation
  • Flu: Immunology & Genetics
  • Global Market for Flu Related Products
  • Epidemiology and Public Health of Influenza
  • Laws and Ethical Issues Related to Flu Research
  • Surveillance Issues and Burden of Disease
  • Entrepreneurs Investment Meet

Special Issues


  •  All accepted abstracts will be published in respective OMICS   International Journals.
  •  Abstracts will be provided with Digital Object Identifier by Cross Ref.

See more at: http://flu.conferenceseries.com/